Introduction
Over the past decade a variety of viral and nonviral vectors has been investigated for gene therapeutic purposes. Especially, viral vectors have been shown to induce high expression of heterologous proteins. In the present study, Semliki Forest virus (SFV) was used as a vector for the in vitro as well as in vivo transfection with several genes. SFV belongs to the genus Alphavirus of the family of the Togaviridae. 1 Alphaviruses consist of a nucleocapsid with one copy of a single-stranded RNA molecule surrounded by an envelope containing spike proteins. The RNA molecule has positive polarity which enables the genomic RNA to start an infection when introduced into the cytoplasm. In addition, the RNA is self-replicating since it encodes its own replicase, and replication results in highlevel expression of the viral proteins in host cells. The viral cDNA has been cloned under the control of a prokaryotic DNA-dependent RNA polymerase such that viral RNA can be transcribed in vitro. The RNA transcripts are fully infectious meaning that delivery into cells suffices to initiate replication and a full infection cycle, resulting resulted in a slight increase in the number of peritoneal macrophages and in a significant increase in the number of neutrophils. In contrast to multiple i.p. injections with commercially available recombinant GM-CSF, i.p. injected SFV-GM-CSF particles activated the macrophages to tumor cytotoxicity. Although treatment of tumor-bearing mice with SFV-GM-CSF particles did not result in prolonged survival, tumor growth was inhibited for 2 weeks. Our findings indicate that macrophage-activating cytokines expressed by the efficient and safe recombinant SFV system when administered i.p. may provide an immunotherapeutic treatment modality additional to current chemotherapeutic treatment of intraperitoneally growing cancers. Gene Therapy (2001) 8, 300-307.
in virus formation. Liljeströ m and Garoff developed a vector system that allows for efficient expression of foreign sequences as part of the SFV replicon. [2] [3] [4] To minimize the incidence of production of fully replicative wild-type viruses, the genes encoding the replicase and structural genes are separated. In addition, to improve biosafety further, the SFV helper construct (containing the structural genes) was mutated in the gene encoding one of the spike proteins. As a result, virus particles cannot infect cells unless they are pretreated with an exogenous protease. The recombinant virus particles that are produced can infect cells only once. Transfection by SFV particles is not restricted to dividing cells; also differentiated cells can be transfected by this system, which may be an advantage over other viral vectors used for transfection.
In the present study we used recombinant SFV particles for in vivo and in vitro transfection. We first investigated in which organs the highest transfection occurred upon intraperitoneal (i.p.) injections with SFV particles. For this purpose, the luciferase gene was used as a reporter gene. Ultimately, we investigated the effect of in vivo transfection with the gene encoding recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) on the tumor cytotoxic potential of the peritoneal cell population in both nontumor-bearing and tumor-bearing mice. GM-CSF is a 18-30 kDa glycoprotein produced by T cells, monocytes and endothelial cells. It stimulates monocytes and macrophages to become tumoricidal both in vitro and in vivo [5] [6] [7] [8] [9] and induces macrophage recruitment. 10 As a tumor model we used murine ovarian tumor cells (MOT cells), a teratocarcinoma which arose spontaneously in female C3HeB/FeJ mice. 11 This model closely resembles disseminated ovarian cancer in humans. 12, 13 In the present study, we investigated the fate and in vivo transfection capacity of recombinant SFV particles administered i.p., by using both genes encoding for a reporter enzyme and a functional protein, to determine whether the application of in vivo transfection could be an effective approach to activate peritoneal macrophages to a tumoricidal state.
Results
In vivo transfection with SFV-luciferase particles To determine the target organs of transfection upon i.p. injection with recombinant SFV particles, mice were injected i.p. with 5 × 10 7 SFV-luciferase particles. At 24 h after injection, the mice were killed and the peritoneal lining, liver, spleen and lungs were isolated. Luciferase activity was expressed in absolute amounts per organ ( Figure 1a ) as well as in relative amounts per gram of organ (Figure 1b) . To calculate these values in the peritoneal lining, we estimated the total surface area of the peritoneal lining at 20 cm 2 . Based on this estimation, we found 99% of the total luciferase activity associated with the peritoneal lining. Approximately 100-to 1000-fold lower amounts of luciferase were detected in lung, spleen and liver. No activity was observed in the organs of mice not injected with SFV-luciferase particles (not shown).
Effects of i.p. SFV-GM-CSF particles on the peritoneal cell population in nontumor-bearing mice Most cells transfected after i.p. injections with SFVluciferase particles, were located in the peritoneal cavity. Subsequently, we determined whether transfection with SFV particles encoding GM-CSF results in sufficient GM-CSF production in the peritoneal cavity to induce an effect on the peritoneal cell population. For this purpose, nontumor-bearing mice were injected i.p. with 5 × 10 7 SFV-GM-CSF particles. Three days after injection, the mice were killed and peritoneal cells were isolated, counted and differentiated into macrophages, lymphocytes and neutrophils. The tumor cytotoxic capacity of the whole cell population was determined. The results were compared with those of mice injected with 5 × 10 7 SFVlacZ particles or phosphate-buffered saline (PBS) (control mice) and in the case of tumor cytotoxic capacity also to mice injected with 5 × 10 6 SFV-GM-CSF particles. Injection of 5 × 10 7 SFV-GM-CSF particles resulted in a significant increase in the number of peritoneal cells isolated 24 h after injection, as compared with control mice treated with PBS or SFV-lacZ (Table 1 ). This increase was mainly caused by an increase in the number of neutrophils. Injection of SFV-lacZ particles resulted in a slight increase in cell number which, however, was not significantly different from the number of cells isolated from control mice.
Cytolytic activity of the peritoneal macrophages was determined using human ovarian tumor cells (A2780) as target cells (Figure 2 ). Peritoneal cells, mainly consisting of macrophages, isolated from mice treated with 5 × 10 7 SFV-GM-CSF particles were approximately four-to 10-fold more cytotoxic towards A2780 cells than cells from the other treatment groups. An additional in vitro stimulation with LPS strongly increased the level of cytolytic activity of cells isolated from mice injected with a low dose of SFV-GM-CSF particles (ie 5 × 10 6 ). The cytolytic activity of cells isolated after injection of a high dose of SFV-GM-CSF particles (ie 5 × 10 7 ) could not be enhanced by an additional in vitro stimulation with LPS, suggesting that the peritoneal cells were already maximally activated in vivo. As cytolytic activity can be correlated to the secretion of nitric oxide (NO) and tumor necrosis factor (TNF) by the peritoneal cells, these mediators were also determined (Figure 3a and b) . Unstimulated cells of all groups secreted very low amounts of NO while no TNF secretion was detected. LPS-stimulated peritoneal cells isolated from mice injected with SFV-GM-CSF showed a strong tendency to produce more NO and TNF than peritoneal cells isolated from control groups, although this difference was not statistically significant. Seventy-two hours after i.p. injection with the SFV particles, the mice were killed and peritoneal cells were isolated and characterized. Data represent the average of four mice. *Significant difference with control group treated with PBS (P р 0.05) and marginally significant with control group treated with SFVlacZ (P р 0.1). **Significant difference with control group treated with PBS or with SFV-lacZ particles (P р 0.05). 
Transfection of MOT cells and peritoneal cells with SFV particles encoding reporter proteins
Mice inoculated with 1 × 10 6 murine ovarian tumor cells (MOT cells) were injected 6 h later with 5 × 10 7 SFVluciferase particles. At 24 h after injection, mice were killed and the cells from the peritoneal cavity (consisting of 1.1 ± 0.3 × 10 6 MOT cells, 1.5 ± 0.1 × 10 6 macrophages, 0.2 ± 0.1 × 10 6 lymphocytes and 0.07 ± 0.02 × 10 6 neutrophils) were isolated and characterized by MayGrü nwald-Giemsa staining. The mean value of luciferase activity per 1 × 10 6 cells isolated from the peritoneal cavity was 432 ± 233 pg (n = 3), which was high compared with the luciferase activity measured in other organs ( Figure 1 ). Subsequently, we determined whether the transfected cells in the peritoneum were MOT cells or peritoneal cells. For this purpose, two mice were inoculated with 2 × 10 6 MOT cells. After 24 h the tumor-bearing mice were injected with 5 × 10 8 SFV-lacZ particles. The peritoneal cells, including MOT, cells were harvested by peritoneal lavage 24 h after injection with the SFV- lacZ particles and subsequently stained for lacZ. As MOT cells are much larger than the peritoneal cells, they are easy to distinguish by their morphology. As a control, peritoneal cells isolated from tumor-bearing mice injected with SFV-luciferase particles and peritoneal cells from a nontumor-bearing mouse were stained for lacZ. While no staining was observed in resident peritoneal cells either from tumor-bearing or from nontumor-bearing mice, maximally 29% of the MOT cells were strongly positive for lacZ staining.
Based on these data with the lacZ reporter gene, we conclude that the luciferase activity of the cells isolated from the peritoneal cavity was coming from transfected MOT cells rather than from transfected peritoneal cells. This would imply that the MOT cells produce 1081 ± 350 pg luciferase per 1 × 10 6 cells.
Transfection of MOT cells with SFV-GM-CSF particles
The amount of GM-CSF secreted by MOT cells transfected with SFV-GM-CSF particles was determined in the culture supernatants of the cells at 0, 24, 48, 72 and 96 h after addition of the particles (Figure 4a ). At a MOI of 1, no significant GM-CSF secretion was observed. However, at a MOI of 10 and 30, GM-CSF secretion was detected within 24 h after transfection. The amount of GM-CSF increased until 72 to 96 h after transfection with SFV-GM-CSF particles to a maximal level of 100 ng per 1 × 10 6 cells at a MOI of 30.
In addition, we determined whether MOT cells exposed to SFV-GM-CSF particles in vivo were transfected in sufficient numbers to measure GM-CSF secretion in vitro. For this purpose, mice inoculated i.p. with 2 × 10 6 MOT cells were injected with 5 × 10 7 SFV-GM-CSF particles. After isolation of the tumor cells from the peritoneal cavity by peritoneal lavage, the amount of GM-CSF secreted was measured at 0, 24, 48, 72 and 96 h after isolation of the cells (Figure 4b ). It is Important to note that transfection of MOT cells in vivo initiated 24 h before isolation of the cells from the peritoneal cavity, meaning that GM-CSF secretion was measured 24, 48, 72, 96 and 120 h after the start of transfection with SFV-GM-CSF particles. At 24 h after isolation of MOT cells (ie 48 h after the initiation of transfection), a maximal concentration of approximately 55 ng GM-CSF per 1 × 10 6 was measured. This amount of GM-CSF did not further increase during a longer culture period. MOT cells isolated from a control mouse injected with SFV-lacZ particles did not show GM-CSF secretion.
Effect of injections with SFV-GM-CSF particles on tumor cell growth
To investigate whether SFV-GM-CSF particles are able to induce an antitumor response in vivo, tumor-bearing mice received multiple injections of 5 × 10 7 or 5 × 10 6 SFV-GM-CSF particles or, as controls, 5 × 10 7 SFV-lacZ particles or PBS. We previously demonstrated that bodyweight correlates well with the number of MOT cells. Therefore, tumor growth was determined by measuring the increase in body weight ( Figure 5 ). In addition, the survival period of the mice was determined. Within the first 10 days after tumor inoculation, a significant inhibition of tumor growth was observed in the group treated with the low dose (5 × 10 6 ) of SFV-GM-CSF particles as compared with the control groups. Injections with the high dose of SFV-GM-CSF particles had no effect on tumor growth. Despite Gene Therapy the initial delay in tumor growth, no significant prolongation of survival was observed in the SFV-GM-CSF group (data not shown).
Figure 4 Secretion of GM-CSF by transfected MOT cells. Secretion of GM-CSF by MOT cells at several time-points after in vitro transfection with SFV-GM-CSF particles with a MOI of 1 (᭜), 10 (), and 30 (̆) (a). In vitro secretion of GM-CSF by MOT cells upon injection with SFV-

Discussion
In the present study we investigated the fate and intraperitoneal effects of i.p. administered recombinant SFV particles. Transfection with vectors derived from SFV is characterized by a broad host range, high protein expression level and cell death.
14 I.p. injection of recombinant SFV particles has been shown to induce both systemic humoral and cellular immune responses. 15, 16 Organ distribution and intraperitoneal effects of these particles, however, were not determined until now. By using recombinant SFV particles that encoded reporter genes such as luciferase and lacZ we demonstrated that upon i.p. injection most of the recombinant protein is produced within the peritoneal cavity. Approximately 100-to 1000-fold lower amounts of recombinant proteins were found in other organs such as liver, spleen and lungs. This result suggests that upon i.p. injection, virus particles are Several studies have demonstrated that GM-CSF has the potency to directly or indirectly stimulate immune cells, ie macrophages and T cells, to tumoricidal activity. 5, 8 In previous studies we investigated the effects of multiple i.p. injections of soluble GM-CSF on the recruitment and activation of peritoneal macrophages to tumor cytotoxicity as a means to treat metastases from ovarian cancer. 10, 17 We found that, in order to induce recruitment and stimulation of peritoneal macrophages, GM-CSF has to be administered three times a day for several days. The advantage of an i.p. injection with a viral vector expressing GM-CSF would be that a single injection could result in a prolonged release of GM-CSF. In addition, several studies have shown that GM-CSF expression by tumor cell themselves induces an effective immune response towards the tumor cells by stimulating T cell responses. [18] [19] [20] [21] [22] This T cell response is sufficient to protect against tumor challenges with nontransduced tumor cells. Furthermore, Rezzani et al 23 
demonstrated that peritoneal cells can be induced to differentiate into dendritic cells when incubated with GM-CSF in vitro.
This means that in vivo transfection with the GM-CSF gene may also affect the peritoneal cell population by increasing the number of dendritic cells. Thus, transfection of i.p. growing tumor cells may not only induce recruitment and/or activation of macrophages as a response to GM-CSF production, but also induce tumorspecific T cell responses. The disadvantage of the autologous tumor vaccine approach involves time-consuming steps such as tumor resection, tumor cell culture and transfection and irradiation of cells. In the present study these steps are circumvented by directly injecting the recombinant particles into the peritoneal cavity, thereby transfecting tumor cells in vivo. Using this approach not only tumor cells but also other cell types in the peritoneal cavity, will be transfected, as can be concluded from our results with the recombinant SFV luciferase particles. As the expression mediated by the alphaviral vector is transient and lytic, biosafety risks such as chromosomal integration and induction of immunological tolerance are avoided.
To determine the potential use of recombinant SFV particles for intraperitoneal immunotherapy, we first determined the effects of SFV-GM-CSF particles on the peritoneal cell population. Injection of recombinant SFV encoding GM-CSF resulted in an increase in the number of peritoneal cells which was mainly due to an increase in neutrophils. This increase depended on the production of GM-CSF as SFV-lacZ particles did not induce a significant rise in the number of neutrophils. In contrast to what we had expected, ie an increase in the number of peritoneal macrophages as seen upon injection of soluble GM-CSF, 10 the number of macrophages did not significantly increase upon i.p. injection of SFV-GM-CSF particles. On the other hand, peritoneal cells isolated from SFV-GM-CSF injected mice were highly tumor cytotoxic without the need of an additional in vitro stimulation with LPS. We previously found that peritoneal cells isolated from mice injected i.p. with soluble GM-CSF do require an additional LPS stimulus to become fully activated. 10, 17 We assume that the combination of GM-CSF and the 'viral infection' provides the full trigger for macrophages to become cytotoxic.
Subsequently, we determined the in vivo antitumor effect of i.p. injected SFV-GM-CSF particles on an i.p. growing tumor. Despite the observed activation of peritoneal macrophages, only a slight delay in tumor growth was observed with a relatively low number of viral particles, ie 5 × 10 6 . It should, however, be noted that the tumor cells employed in these studies grow extremely fast upon i.p. inoculation. A delay in tumor growth is in general only seen using high-dose chemotherapeutics (unpublished observation). Finally, we demonstrated that intraperitoneally growing tumor cells are readily transfected by i.p. injected recombinant SFV particles resulting in the production of high amounts of recombinant protein. In analogy to the cellular immune responses induced upon immunization with in vitro cytokine-transfected tumor cells, 15, 16 it is expected that these in vivotransfected tumor cells may induce a tumor-specific T cell response. Unfortunately, this fast-growing tumor model does not allow for the evaluation of this response as the mice have to be killed before a tumor-specific T cell response can be expected.
In conclusion, we demonstrated that the i.p. injection of recombinant SFV particles results in high level expression of the recombinant protein in the peritoneal cavity. This application of recombinant SFV particles was used for the activation of peritoneal macrophages to tumor cytotoxicity by GM-CSF resulting in a low, but significant, delay in tumor growth of a very rapidly growing intraperitoneal tumor. Further studies will have to prove the effciency of a combination of this kind of immuno/gene therapy with current chemotherapeutic treatment of peritoneal cancers.
Materials and methods
Animals
Female C3HeB/FeOrl-U mice (8-12 weeks), obtained form the Central Animal Laboratory of the University of Utrecht were used for all experiments. The animals received care in accordance with the institution's guidelines. The in vivo study was approved by the faculty committee of animal studies of the University of Groningen.
Cell cultures
Baby hamster kidney cells (BHK-21 cells) were obtained from the American Type Culture Collection (No. CCL-10). BHK-21 cells were cultured in Glasgow minimum essential medium (GMEM) supplemented with 5% fetal calf serum (FCS), 0.075% NaHCO 3 , 2 mm glutamine, tryptose phosphate broth (3 g/l), 25 mm Hepes pH 7.6, penicillin G/streptomycin (100 U/ml; 100 g/ml) at 37°C and 5% CO 2 in humidified air. Cells were passaged twice weekly. All media and supplements were obtained from Gibco (Paisley, UK) except for tryptose phosphate broth which was obtained from Difco (Detroit, MI, USA).
Murine ovarian tumor cells (MOT cells, kindly provided by Dr M Bernsen, University of Utrecht, The Netherlands) were passaged once weekly in vivo by injecting 5 × 10 5 cells i.p. into a recipient C3HeB mouse. When the MOT cells were used for in vivo studies, mice were inoculated i.p. with 1 × 10 5 cells in 1 ml injection volume. For in vitro studies, MOT cells were cultured in complete RPMI 1640 culture medium for maximally 96 h.
Peritoneal cell isolation
Mice were killed by cervical dislocation. Peritoneal cells were harvested by peritoneal lavage of the peritoneal cavity with 4 ml ice-cold RPMI 1640 medium supplemented with 2 mm glutamine and penicillin G/streptomycin (100 U/ml; 100 g/ml). Cells were centrifuged at 350 g for 10 min. Subsequently, the pellet was resuspended in culture medium for further use. Cell characterization was based on May-Grü nwald-Giemsa staining.
Preparation of recombinant SFV particles
The pSFV3GM-CSF, pSFV3LacZ, pSFV3Luc3 plasmids were isolated using the Quiagen midi plasmid purification kit (Qiagen, Leusden, The Netherlands) and were linearized by digestion with SpeI (Gibco-BRL, Life Technologies, Paisley, UK). RNA was synthesized from the linearized DNA by in vitro RNA transcription (MEGAscript (SP6); Ambion, Sanbio, Uden, The Netherlands). The capping analogue was obtained from Gibco-BRL. Fifteen g SFV3GM-CSF, SFV3LacZ, SFV3Luc and 7.5 g SFV-Helper2 RNA were admixed and cotransfected into 8 × 10 6 BHK-21 cells/800 l by electroporation using the Biorad (Hercules, CA, USA) Gene Pulser II (two pulses of 850 V/25 F). After pulsing, the cells were suspended in 10 ml complete GMEM culture medium and cultured for 36 h at 37°C and 5% CO 2 . The medium, containing the SFV-GM-CSF, SFV-lacZ or SFV-luc particles, was removed from the BHK-21 cells. The medium containing the recombinant SFV particles was centrifuged twice in a JA20 rotor (Beckman, St Paul, MN, USA) at 1800 r.p.m. (ie 40 000 g at r max ) to remove cells and cellular debris.
Purification of virus particles
After production, 8 ml of medium, containing recombinant SFV particles, was transferred to a SW 31 tube. Then 2 ml of a 15% sucrose solution (w/v) and 1 ml of a 60% sucrose solution (w/v) in TNE (50 mm Tris-Cl, 100 mm NaCl, 1 mm EDTA, pH 7.4) were pipetted underneath the Gene Therapy medium. The tubes were centrifuged at 30 000 r.p.m. (154 000 g at r max ) for 2.5 h at 4°C in a SW 41 rotor (Beckman) to sediment the virus on to the 60% sucrose cushion. Half of the 15% and half of the 60% sucrose layer were collected using a needle pinned into the tube at the interface between the 15 and 60% sucrose layer. Sucrose was removed from the virus solution by overnight dialysis against TNE using a dialysis cassette (10 000 MWCO, Slide-A-Lyzer, 10K; Pierce, Rockford, IL, USA). The virus solution was concentrated approximately 10-fold (Centricon 30 filter; Millipore, Bedford, MA, USA), quickly frozen in liquid N 2 and stored in aliquots at −80°C.
Activation of SFV particles
Recombinant SFV particles obtained using the Helper2 construct need to be activated by chymotrypsin treatment to cleave the mutated spike proteins. Therefore, immediately before use, the SFV particles were incubated with 1/20 volume of ␣-chymotrypsin (10 mg/ml; Fluka Chemie, Zwijndrecht, The Netherlands) for 30 min at room temperature. Subsequently, ␣-chymotrypsin was inactivated by the addition of 0.5 volume of aprotinin (2 mg/ml; Sigma, St Louis, MO, USA).
Titer determination of SFV particles
For determination of the titer of the recombinant SFV particles a monolayer of BHK-21 cells in an eight-well culture chamber slide (Nunc, Life Technologies, Paisley, UK) was infected with a 10× dilution series of activated SFV particles. Infection in a minimal volume (100 l) in GMEM culture medium without FCS was performed during a 1-h incubation period, then 200 l GMEM with FCS was added and the cells were incubated overnight. Subsequently, the medium was removed from the cells and the cells were immediately fixed for 10 min in acetone and dried for 30 min. Polyclonal rabbit anti-replicase (nsP3) antibody was added (kind gift from Dr T Ahola, Biocentre Viiki, Helsinki, Finland) as a primary antibody. The cells were washed in PBS and FITC-labeled goat-antirabbit IgG was added as a secondary antibody. The positive cells were counted in the dilution sample containing 25-150 positive cells per well. The titer was calculated after correcting for the dilution factor and the dilution caused by the activation and the volume of particles added. The number of positive cells was determined by fluorescence microscopy. Virus titer was calculated as follows: number of positive cells × dilution factor × reciprocal volume.
Luciferase activity assay For measuring the luciferase activity, organs were thawed and cut into pieces. Subsequently, a single cell suspension was made using a polytron. Tissue-derived cells were lysed in 1 ml (or 2 ml in the case of the livers) of a 1:5 dilution of lysis buffer (Luciferase Assay Kit; Promega, Madison, WI, USA) according to the manufacturer's protocol. The peritoneal cells were resuspended in 50 l lysis buffer. Cell-free extracts were incubated for 15 min at room temperature, followed by centrifugation for 5 min in an Eppendorf centrifuge to remove cellular debris. Immediately before the measurement, 20 l of the clear supernatant of the samples was mixed with 100 l of substrate solution (Luciferase Assay Kit; Promega). Luciferase signal was determined (Lucy-1 Apparatus, Anthos Labtech Instruments, Salzburg, Austria). A standard curve, using luciferase (Luciferase assay kit; Promega) was used to calculate the amount of luciferase in the samples.
Cytotoxicity assay
Tumoricidal activity of macrophages was measured as described by Daemen et al 24 Tumor growth in mice At day 0 mice (n = 5 per group) were inoculated i.p. with 1 × 10 5 MOT cells. At day −2, 3 and 7, mice were injected i.p. with 5 × 10 7 and 5 × 10 6 purified SFV-GM-CSF particles. Two groups treated either with SFV particles encoding the genome of a pSFV1 plasmid without a recombinant protein or with phosphate-buffered saline (PBS, pH 7.4), served as controls. Mice were weighed to monitor the tumor growth. In addition, the survival period was determined.
TNF assay TNF secretion was measured by an L929 assay. Briefly, 4 × 10 4 L929 cells in 100 l culture medium were added to 100 l of two-fold dilutions of the culture supernatants in a flat-bottomed 96-well plate. To increase the TNF sensitivity of the L929 cells, 2 g of actinomycin D (Sigma) per ml cell suspension was added. After a 18-20 h incubation period, the cells were fixed with 25 l of glutaraldehyde (25% v/v solution; Sigma). After a 15 min incubation, the supernatant was removed and the cells were washed with tap water and stained with 0.05% methylene blue for 20 min. Subsequently, the cells were washed several times and the methylene blue was extracted from the cells by adding 200 l of 0.33 m hydrochloric acid per well. The optical density was measured at 620 nm in a microtiter plate reader. A standard curve with recombinant murine TNF-␣ (Boehringer Mannheim, Mannheim, Germany) was used to determine TNF concentrations in the culture supernatants. One unit TNF was defined as the reciprocal dilution factor of a sample causing 50% lysis of L929 cells.
Nitric oxide assay NO release by the peritoneal cells was measured by adding 100 l Griess reagent (1.0% sulphanylamide, 2.5% phosphoric acid, 0.1% N-naphtyl-ethylene-diamine) to 100 l of culture supernatant. After a 10-min incubation period at room temperature, optical density of the solutions was measured at 550 nm using a microtiter plate reader. A standard curve with sodium nitrite was used for calculating the final NO concentration in the culture supernatants.
␤-Galactosidase staining Cells were fixed in 2% paraformaldehyde and 0.2% glutaraldehyde (both from Sigma). Then cells were incubated in 0.1% X-gal diluted in Hepes buffer (pH 8, 5 mm K 3 Fe(CN) 6 , 5 mm K 4 Fe(CN) 6 ț3H 2 O, 2 mm MgCl 2 ț6H 2 O). After incubation for 2 h, the staining reaction was stopped by removing the X-gal solution.
GM-CSF ELISA
The amount of GM-CSF in culture supernatants of cells transfected with SFV-GM-CSF particles was determined by a capture ELISA. Briefly, a 96-well plate was coated with 2 mg/ml rat anti-mouse GM-CSF monoclonal antibody (ITK Diagnostics) and incubated overnight at 4°C. Nonspecific binding was blocked by incubating the wells for 30 min with blocking buffer (PBS supplemented with 1% Nutricia Protifar; Zoetermeer, The Netherlands). Subsequently, culture supernatants were added to the wells and incubated for 2.5 h at room temperature. Then, 2 mg/ml biotinylated rat anti-mouse GM-CSF monoclonal antibody was added and the mixture was incubated for 1 h at room temperature. Streptavidin-horseradish peroxidase conjugate (ITK Diagnostics, Uithoorn, The Netherlands) was added (1:1000 dilution), followed by addition of the substrate OPD (0.2 mg/ml PBS) containing H 2 O 2 to start the enzymatic reaction and stopped by adding 2 m H 2 SO 4 . PBS containing 0.05% Tween was used as a washing buffer between the different incubation periods. Optical density was measured at 492 nm using a microtiter plate reader. A standard curve with rmGM-CSF (Peprotech, Rocky Hill, NJ, USA) was used to calculate the concentration of GM-CSF in the samples.
Statistics
The Student's t-test was used for comparison between groups. P values Ͻ0.05 were considered significant.
